


01702.401600

PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Application of:	)	
GUSTAV GAUDERNACK, ET AL.	)	Examiner: Christopher Nichols, Ph.D.
Application No.: 09/674,913	)	Group Art Unit: 1647
Filing Date: May 25, 2001	)	
Int'l Appl. No.: PCT/NO99/00141	)	
Int'l Appl. Filing Date: April 30, 1999	)	
For: FRAMESHIFT MUTANTS OF	)	November 3, 2003
BETA-AMYLOID PRECURSOR	)	
PROTEIN AND UBIQUITIN-B	)	
AND THEIR USE	)	

**Mail Stop Sequence**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING

Sir:

During a telephone call of October 16, 2003, the Examiner indicated that the above-identified application is in condition for allowance except for compliance with the sequence listing requirements. More specifically, the Examiner stated that several of the nucleic acid and amino acid sequences shown at pages 12, 13, 18 and 19 are not listed in the originally filed Sequence Listing. The Examiner requested that a substitute Sequence Listing be submitted to include those missing sequences.

In response, Applicants submit herewith a computer readable form and a paper copy of a substitute Sequence Listing under 37 C.F.R. § 1.821-1.825, and a Statement Under 37 CFR §1.821(f) specifying that the Sequence Listing information

recorded in computer readable form on the attached diskette is identical to the written Sequence Listing.

Conclusion

Applicants submit that the application is in condition for allowance. Accordingly, issuance of an early Notice of Allowance is respectfully requested.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

  
John W. Behringer  
Registration No. 23,086  
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

DC\_MAIN 148755v1